Retraction: Quantitative GABA magnetic resonance spectroscopy as a measure of motor learning function in the motor cortex after subarachnoid hemorrhage - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Withdrawal of the Study: Assessing Motor Learning in the Motor Cortex Post-Subarachnoid Hemorrhage Using Quantitative GABA Magnetic Resonance Spectroscopy

  • August 21, 2026

Share

Clinical Scorecard: Withdrawal of the Study: Assessing Motor Learning in the Motor Cortex Post-Subarachnoid Hemorrhage Using Quantitative GABA Magnetic Resonance Spectroscopy

At a Glance

CategoryDetail
ConditionSubarachnoid Hemorrhage
Key MechanismsMotor learning function assessment using GABA magnetic resonance spectroscopy
Target PopulationPatients post-subarachnoid hemorrhage
Care SettingNeurology research

Key Highlights

  • Study retracted due to inaccuracies in reported data
  • Issues identified in age, WFNS grade, and GABA measurement values
  • MRI scanner used for data collection is no longer available
  • Conclusions of the study are unsupported by the data
  • Retraction authorized by Frontiers' editorial team

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not applicable due to study retraction

          Not applicable due to study retraction

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Retraction: Quantitative GABA magnetic resonance spectroscopy as a measure of motor learning function in the motor cortex after subarachnoid hemorrhage

            • August 21, 2026

            Related Content

            American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy

            This American Epilepsy Society (AES) practice guideline provides updated, evidence-based recommendations for the management of epilepsy in infants and children aged 1 month to <36 months.

            • by

            • August 14, 2026

            • 2 min
            Pediatric neurologist Dr. John Gaitanis to lead NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development

            • August 21, 2026

            FDA approves tau PET imaging agent

            The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.